Johnson & Johnson (JNJ) Q4 2025 (USD): Adj. EPS 2.46 (exp. 2.49), Revenue 24.6bln (exp. 24.15bln); guides initial FY26 Adj. EPS 11.53 (exp. 11.46), Revenue 100.5bln (exp. 98.5bln)
- EPS growth skewed to H2 over H1 in 2026.
Context
Johnson & Johnson reported Q4 2025 results with a slight miss on adjusted EPS, although revenue exceeded expectations. The guidance for FY26 reflects a positive outlook, with projected EPS and revenue both above consensus, suggesting investor confidence in a stronger second half of the year, which could influence market sentiment positively.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#JOHNSON & JOHNSON#JNJ.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#DXY#GLOBAL NEWS#US EQUITIES